Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$152.33 USD
+2.02 (1.34%)
Updated May 3, 2024 04:00 PM ET
After-Market: $152.35 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ALNY 152.33 +2.02(1.34%)
Will ALNY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ALNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALNY
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
ALNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
Annexon (ANNX) to Report Q1 Earnings: What's in the Cards?
Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics
Other News for ALNY
Alnylam Pharma (ALNY) Receives a Hold from Oppenheimer
RBC Capital Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Alnylam Pharmaceuticals Inc (ALNY) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Zimmer Biomet Holdings (ZBH)
ALNY Stock Earnings: Alnylam Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024